Bio-Techne

Nikon Instruments Inc. and Bio-Techne announce partnership to expand access to innovative spatial biology services

Retrieved on: 
Thursday, March 28, 2024
Nikon, Health, Drug discovery, Partnership, Research, Bio-Techne, Disease, Diagnosis, Workflow, Nikon Instruments, Microscope

MELVILLE, N.Y., March 28, 2024 /PRNewswire/ -- Nikon Instruments Inc. (Nikon) is pleased to announce that they have entered into a partnership with Lunaphore , part of Bio-Techne Corporation's Spatial Biology Division, to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Key Points: 
  • MELVILLE, N.Y., March 28, 2024 /PRNewswire/ -- Nikon Instruments Inc. (Nikon) is pleased to announce that they have entered into a partnership with Lunaphore , part of Bio-Techne Corporation's Spatial Biology Division, to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
  • Through this partnership, in addition to access to the COMET™ platform, Nikon will be able to provide its customers with access to HORIZON™ , Lunaphore's image analysis software designed for analyzing COMET™ hyperplex images, to further streamline image analysis workflow.
  • Researchers and clinicians can leverage the COMET™ platform by Lunaphore to unlock the full potential of spatial biology for their research objectives.
  • "Spatial biology is a dynamic area of innovation that will shed new light on healthcare and further our understanding of human disease and health."

BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES

Retrieved on: 
Thursday, March 28, 2024
Health, COMET, Drug discovery, Partnership, Research, Bio-Techne, Disease, Diagnosis, Workflow, Nikon Instruments, Microscope

MINNEAPOLIS, March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore , part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Key Points: 
  • MINNEAPOLIS, March 28, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore , part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
  • Together, Lunaphore and the Nikon BioImaging Lab will be able to leverage their complementary expertise in microscopy-based imaging and analysis to bring COMET technology and spatial biology to the greater scientific community.
  • Researchers and clinicians can leverage the universal end-to-end product suite to unlock the full potential of spatial biology for their research objectives.
  • "Spatial biology is a dynamic area of innovation that will shed new light on healthcare and further our understanding of human disease and health."

BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA

Retrieved on: 
Friday, March 22, 2024
Certification, Acute leukemia, Kit, BCR-ABL, Patient, CML, Class, Bio-Techne, Sale, Cancer, IVDR, Diagnosis, Workflow, ABL1, Safety, Liquid biopsy, TKI, Physician, IVDD, Medical device

MINNEAPOLIS, March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.

Key Points: 
  • Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.
  • The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia (CML) patients.
  • The highly sensitive qPCR-based in vitro diagnostic test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to determine their response to tyrosine kinase inhibitor (TKI) therapy.
  • CML patients must undergo regular monitoring to ensure that they continue to receive the most appropriate treatment for their cancer.

BIO-TECHNE'S ADVANCED CELL DIAGNOSTICS (ACD) SETS NEW STANDARD IN SPATIAL BIOLOGY WITH PROTEASE-FREE RNASCOPE MULTIOMICS

Retrieved on: 
Monday, January 29, 2024
Patient, Research, Bio-Techne, Bladder cancer, Mass meeting, RNA, Poster, Workflow, Protein, Biomarker, Data analysis, Messenger, COMET, Publication, ACD, Vaccine

MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow. Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays. ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.

Key Points: 
  • Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using industry-leading RNAscope™ technology.
  • MINNEAPOLIS, Jan. 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD) , a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.
  • Optimized for same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology, the newly developed RNAscope spatial multiomics workflow is compatible with both manual and automated assays.
  • ACD's novel protease-free RNAscope workflow is incorporated in Bio-Techne's recently announced best-in-class multiomics application on Lunaphore's COMET platform.

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio

Retrieved on: 
Friday, January 26, 2024
Bristol Myers Squibb, Cytotoxicity, Research, Incidence, Melanoma, ROW, Biotechnology, AstraZeneca, Ipilimumab, HDAC, Carcinoma, Bone marrow suppression, Growth, BioNTech, Bio-Techne, NSCLC, Combination therapy, Investment, Disease, BMS, USD, FDA, Diarrhea, HBM, Hair loss, Merck, CTLA4, Immune system, Pharmaceutical industry

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is estimated to grow by USD 2.23 billion from  2023 to 2028, growing at a CAGR of 15.11%. High target affinity and specificity of CTLA4 inhibitors are notably driving the growth. Despite several approved therapies, the treatment landscape for advanced or recurrent cancer lacks sufficient drug responsiveness. Available therapies often lead to severe side effects, reducing patient compliance. Chemotherapy, the current standard of care for advanced cancers, causes significant adverse effects like bone marrow suppression, diarrhea, and hair loss. Similarly, surgery and radiation therapy have limitations in treating recurring carcinomas like melanomas. Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.

Key Points: 
  • High target affinity and specificity of CTLA4 inhibitors are notably driving the growth.
  • Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.
  • The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
  • The HDAC (histone deacetylase) inhibitors market is estimated to grow at a CAGR of 7.73% between 2022 and 2027.

Depixus Appoints Steve Klose as Chief Commercial Officer to Drive the Commercialization of Its Groundbreaking MAGNA™ Technology

Retrieved on: 
Thursday, January 11, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Health Technology, Research, Data Analytics, Software, Science, Clinical Trials, Multimedia, Interactome, Laboratory, Bio-Techne, Growth, Management

Interactomics pioneer Depixus has appointed experienced life sciences sales leader, Steve Klose, to the newly created role of Chief Commercial Officer from January 16, 2024.

Key Points: 
  • Interactomics pioneer Depixus has appointed experienced life sciences sales leader, Steve Klose, to the newly created role of Chief Commercial Officer from January 16, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240111216042/en/
    Steve Klose is taking up the role of Chief Commercial Officer at Depixus in January 2024.
  • Prior to this, he held a variety of commercial leadership roles at Bio-Techne, SciKon Innovation, Quanterix, Mesoscale Discovery and Varian.
  • Gordon Hamilton, CEO of Depixus, said, “I’m thrilled to have Steve joining the team to lead our commercial strategy following the launch of the MAGNA technology access program.

Western Blotting Global Market Outlook to 2028, Featuring Leading Players Advansta, Bio-Rad Laboratories, Cell Signaling Technology, Li-Cor Biosciences, Merck, Perkinelmer and Thermo Fisher Scientific - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Health, Other Health, Cell Signaling Technology, Protein, Agriculture, Antibody, Research, Prevalence, Lyme disease, ELISA, Disease, ESG, Thermo Fisher Scientific, PCR, Bio-Techne, HIV, Merck, Polymerase chain reaction, Growth, Bio-Rad Laboratories, Diagnosis, Environment

Increasing cases of HIV and Lyme disease are contributing to the demand for Western blotting.

Key Points: 
  • Increasing cases of HIV and Lyme disease are contributing to the demand for Western blotting.
  • Thus, Western blotting is being used increasingly to effectively differentiate between HIV and other antibodies and provide precise results.
  • Therefore, experts are increasingly recommending this test, and this is expected to drive market growth over the forecast period.
  • The report also covers market projections for 2028 and the market share for key market players.

LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLS

Retrieved on: 
Thursday, December 14, 2023
Research, Spatial, Health, COMET, SIB, AI, Bio-Techne, Medical imaging

MINNEAPOLIS, Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics , have been awarded Innosuisse funding for an innovation project.

Key Points: 
  • MINNEAPOLIS, Dec. 14, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore , a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics , have been awarded Innosuisse funding for an innovation project.
  • The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research.
  • Spatial biology utilizes detailed tissue analysis and intracellular interactions to enable profound insights in cancer biology, immuno-oncology, and other research fields.
  • However, technical hurdles still stand in the way of spatial biology technologies entering clinics and becoming guiding tools for personalized therapies.

Arachidonic Acid Market to increase by USD 114.82 million between 2023 to 2028; Rising awareness about preventative healthcare boosts the market - Technavio

Retrieved on: 
Thursday, December 7, 2023
Infant, Leukotriene, PerkinElmer, Thermo Fisher Scientific, BASF SE, Arachidonic acid, USD, Cayman Chemical Company, BASF, Prostaglandin, Bio-Techne, Geography, Growth, SE, International, Merck Group, Thromboxane, Dietary supplement, Beauty salon

NEW YORK, Dec. 7, 2023 /PRNewswire/ -- The arachidonic acid market size is expected to grow by USD 114.82 million from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 7, 2023 /PRNewswire/ -- The arachidonic acid market size is expected to grow by USD 114.82 million from 2023 to 2028.
  • In addition, the growth momentum of the market will progress at a CAGR of  7.23% during the forecast period, according to Technavio.
  • Rising awareness about preventative healthcare is notably driving the arachidonic acid market.
  • However, factors such as the availability of substitutes for arachidonic acid may impede market growth.

BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE

Retrieved on: 
Monday, November 27, 2023
Cytokine, Research, Diagnosis, Gene editing, ISH, Nature, FDA, Prostate cancer, Calendar, Workflow, ACD, Conference, Drug discovery, Bio-Techne, EST, Antibody, ELISA, Cryptocurrency, Medical imaging

MINNEAPOLIS, Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST.

Key Points: 
  • MINNEAPOLIS, Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST.
  • A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide.